Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Hoeller

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Cancer Treatment Reviews|June 23, 2015
Gaining momentum: New options and opportunities for the treatment of advanced melanomaOlivier Michielin, Christoph Hoeller
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 27, 2020
Peter Koelblinger, Van Anh Nguyen, Christoph Hoeller, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2017
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumorsReinhard Dummer, Christoph Hoeller, Isabella Pezzani Gruter, et al.
Melanoma Research|February 26, 2019
Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damageSusanne Kimeswenger, Ulrike Mann, Christoph Hoeller, et al.
Cancer Immunology, Immunotherapy : CII|July 4, 2016
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaChristoph Hoeller, Olivier Michielin, Paolo A Ascierto, et al.
The American Journal of Case Reports|February 23, 2025
Rare Lacrimal Gland Melanoma: A Case Report and Treatment InsightsReinhard Told, Ana-Iris Schiefer, Christoph Hoeller, et al.
Oncotarget|March 13, 2019
The interplay of CDK4 and CDK6 in melanomaKaroline Kollmann, Coralie Briand, Florian Bellutti, et al.
Molecular Medicine (Cambridge, Mass.)|February 28, 2003
Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significanceEdgar Selzer, Christiane Thallinger, Christoph Hoeller, et al.
British Journal of Cancer|July 28, 2020
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectivesMark R Middleton, Christoph Hoeller, Olivier Michielin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Erlotinib and bevacizumab have synergistic activity against melanomaNikolaus Schicher, Verena Paulitschke, Alexander Swoboda, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Cancer Treatment Reviews|June 23, 2015
Gaining momentum: New options and opportunities for the treatment of advanced melanomaOlivier Michielin, Christoph Hoeller
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 27, 2020
Peter Koelblinger, Van Anh Nguyen, Christoph Hoeller, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2017
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumorsReinhard Dummer, Christoph Hoeller, Isabella Pezzani Gruter, et al.
Melanoma Research|February 26, 2019
Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damageSusanne Kimeswenger, Ulrike Mann, Christoph Hoeller, et al.
Cancer Immunology, Immunotherapy : CII|July 4, 2016
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaChristoph Hoeller, Olivier Michielin, Paolo A Ascierto, et al.
The American Journal of Case Reports|February 23, 2025
Rare Lacrimal Gland Melanoma: A Case Report and Treatment InsightsReinhard Told, Ana-Iris Schiefer, Christoph Hoeller, et al.
Oncotarget|March 13, 2019
The interplay of CDK4 and CDK6 in melanomaKaroline Kollmann, Coralie Briand, Florian Bellutti, et al.
Molecular Medicine (Cambridge, Mass.)|February 28, 2003
Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significanceEdgar Selzer, Christiane Thallinger, Christoph Hoeller, et al.
British Journal of Cancer|July 28, 2020
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectivesMark R Middleton, Christoph Hoeller, Olivier Michielin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Erlotinib and bevacizumab have synergistic activity against melanomaNikolaus Schicher, Verena Paulitschke, Alexander Swoboda, et al.
Pageof 8